Aura Biosciences (AURA) EBITDA (2020 - 2026)
Aura Biosciences' (AURA) quarterly EBITDA came in at -$34.9 million in Q1 2026, down 20.08% YoY from -$43.6 million in Q1 2025, and down 28.01% on a QoQ basis from -$27.2 million in Q4 2025.
Aura Biosciences (AURA) EBITDA (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of EBITDA data on file, last reported at -$34.9 million in Q1 2026.
- Quarterly EBITDA fell 20.08% year-over-year to -$34.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.6 million (down 15.35% YoY) and the FY2025 annual result came in at -$112.8 million, down 17.35% from the prior year.
- EBITDA slipped to -$34.9 million in Q1 2026, from -$27.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$12.8 million in Q1 2022 to a low of -$34.9 million in Q1 2026.
- A 5-year average of -$22.9 million and a median of -$22.8 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA plunged 116.15% — and 2025, when it advanced 2.05%.
- Tracing AURA's EBITDA over 5 years: stood at -$17.6 million in 2022, then plunged by 40.71% to -$24.8 million in 2023, then fell by 12.2% to -$27.8 million in 2024, then climbed by 2.05% to -$27.2 million in 2025, then dropped by 28.01% to -$34.9 million in 2026.
- The last three EBITDA figures came in at -$34.9 million (Q1 2026), -$27.2 million (Q4 2025), and -$27.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | -48.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.07 Mn |
| Mar 31, 2026 | -34.87 Mn |
| Dec 31, 2025 | -27.24 Mn |
| Sep 30, 2025 | -27.91 Mn |
| Jun 30, 2025 | -28.61 Mn |
| Mar 31, 2025 | -29.04 Mn |
| Dec 31, 2024 | -27.81 Mn |
| Sep 30, 2024 | -23.23 Mn |
| Jun 30, 2024 | -22.76 Mn |
| Mar 31, 2024 | -22.31 Mn |
| Dec 31, 2023 | -24.78 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -20.28 Mn |
| Mar 31, 2023 | -19.44 Mn |
| Dec 31, 2022 | -17.61 Mn |
| Sep 30, 2022 | -16.06 Mn |
| Jun 30, 2022 | -13.82 Mn |
| Mar 31, 2022 | -12.81 Mn |
| Dec 31, 2021 | -11.63 Mn |
| Sep 30, 2021 | -8.90 Mn |